SentreHEART is a medical device company that manufactures the LARIAT technology for catheter-based, non-implant left atrial appendage closure (LAAC). The company also develops the LARIAT Suture Delivery Device for suture placement and knot tying in surgical procedures. SentreHEART is privately owned, based in Redwood City, California, and was founded in 2005. The LARIAT device has received FDA 510(k) clearances in 2006, 2009 and 2014 and holds a CE Mark in Europe. The company will use proceeds from its recent financing to complete the aMAZE randomized pivotal clinical trial evaluating LARIAT as an adjunct to pulmonary vein isolation (PVI) ablation in patients with persistent or longstanding persistent atrial fibrillation. The aMAZE trial aims to demonstrate reduced recurrent AFib and to further define the clinical role of LAA closure. SentreHEART manufactures the LARIAT Suture Delivery Device, which enables remote delivery of a 40mm pre-tied polyester suture loop for immediate and complete soft tissue closure through access as small as 4.3mm with no metal, clips, or fabrics left behind. The device facilitates suture placement and knot tying for ligation and approximation in surgical applications. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada. The company estimates the LARIAT may have application in more than 2.5 million procedures annually, representing a $1.6 billion global market opportunity. SentreHEART reports early commercial success with rapid physician adoption worldwide and has added several veteran medical device executives to its leadership team to support growth. The company says the new financing will enable expansion of commercialization and continued support for its steady growth.

Total raised

$61M

Funding rounds

2

Latest round

Series D

Latest activity

Sep 2016